Skip to content
Kalpvruksh Markets
Offline Log in

INVICTANSEOffline

INVICTA DIAGNOSTIC · INE0XJ501010 · Small Cap · #2456
68.30+0.30 (+0.44%)last close · 05 Nov 2026
Prev close
68.00
Open
—
High
—
Low
—
Volume
—
Mkt cap (6-mo avg)
₹90 cr

Loading minute bars…

NSE 1-minute bars from our CandleApi gateway (history from 21 Jul 2026); longer timeframes are built from them. Prices not adjusted for corporate actions.

INVICTA is a Small Cap company, #2456 by market cap.

Overview

What the data says, line by line

A description, never a buy or sell word · tap a line for its detail

  • no promoter pledge
  • nothing scheduled or restricting

How big is it?

six-month average market cap

Market capitalisation
₹90 cr
Rank
#2456
Cap band
Small Cap
Nearest cut-off — Mid / Small
−99.74% from ₹34,190 cr
Clear of the cut-off

Our own six-month average, computed the way AMFI computes it; the published classification is on the market cap page.

Did buyers take delivery?

latest session · 2026-11-05

vs its own normal
0.5×
median 3,200
Delivered
1,600
Of volume
100%

Price & trend

Price & trend

Not enough price historyFigures need 60 sessions of NSE prices.

Ownership

Who owns the company

% of all shares, by quarter

GroupMar 26Sep 26
Promoters66.7%66.7%
FPI4.2%1.5%
Mutual funds——
Other DII4.3%4.3%
Individuals18.7%21.1%
Others6.1%6.4%

From the company’s quarterly shareholding pattern. Changes in percentage points against the quarter before. No quarters are on record between Sep 2022 and Jun 2025.

Promoter pledge

Sep 26

Of promoters’ holding
none
Of all shares
none
Mar 26 noneSep 26 none

Holders

Sep 26

All shareholders
410
Individuals
338

Which funds bought and sold

No fund holds this companyNo Indian mutual fund disclosed a position at the last quarter end.

Fund ownership is a quarterly disclosure and counts Indian passive schemes only.

Results

Results

Events & filings

Disclosures & deals

last six months · NSE filings

  • Board outcome
    Invicta Diagnostic Limited has informed the Exchange regarding Outcome of Board Meeting held on September 18, 2026 wherein Board considered and approved the proposed business outlook and forward-looking guidance to be communicated by the Chairman & Managing Director and Chief Financial Officer to th
    18 Sept 2026
  • Board outcome
    Invicta Diagnostic Limited has informed the Exchange regarding Outcome of Board Meeting held on August 25, 2026.
    26 Aug 2026
  • Board outcome
    Invicta Diagnostic Limited has informed the Exchange regarding Outcome of Board Meeting held on July 29, 2026. Board at its meeting held today
    30 Jul 2026
  • Scheme / acquisition
    Update-Acquisition (including agreement to acquire)-XBRL INVICTA DIAGNOSTIC LIMITED has informed the Exchange regarding Update-Acquisition/Scheme/Sale/Disposal-XBRL
    15 Jun 2026
  • Scheme / acquisition
    Invicta Diagnostic Limited has informed the Exchange that Porteus Medical LLP a subsidiary LLP of the Company, has incorporated a Limited Liability Partnership namely Porteus Pathogenius LLP and Consequent to the above incorporation, Porteus Pathogenius LLP has become a Step-Down Subsidiary of the C
    15 Jun 2026
  • Scheme / acquisition
    Invicta Diagnostic Limited has informed the Exchange about Incorporation of Step-Down Subsidiary LLP
    02 Jun 2026
  • Bulk deal: BUY
    1,93,600 at ₹73.79 — BIRCHWOOD MULTI STGY FND OPENENDED PCC LTD - BIRCHWOOD GLOBAL ALPHA FUND
    05 Aug 2026
  • Bulk deal: SELL
    1,93,600 at ₹73.79 — PINE OAK GLOBAL FUND
    05 Aug 2026

Latest shown; 9 in six months on all disclosures.

INVICTA: only ratings, pledges, insider and takeover disclosures, buybacks, schemes, board outcomes and deals are listed. All deals.

Market capitalisation is our own six-month average, computed the way AMFI computes it; the published classification is on the market cap page. Fund ownership is a quarterly disclosure and counts Indian passive schemes only. Nothing here is advice, a recommendation, or a view on the company.